The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Hosted on MSN1d
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You TradeVertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile, the Dow ...
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...
Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...
Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.
Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...
The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43 rd Annual J.P ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback